Millennium Management’s Structure Therapeutics GPCR Stock Holding History

Millennium Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-234,000	Closed	-$6.35M	–	6061
2024 Q4	$6.35M	Buy	234,000 +25,000	+12%	+$887K	﹤0.01%	2609
2024 Q3	$9.17M	Buy	209,000 +126,500	+153%	+$4.89M	﹤0.01%	2251
2024 Q2	$3.24M	Buy	+82,500	New	+$3.39M	﹤0.01%	3120
2024 Q1	–	Sell	-70,000	Closed	-$2.85M	–	6356
2023 Q4	$2.85M	Buy	+70,000	New	+$4.01M	﹤0.01%	3295

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Millennium Management's GPCR Position: Q1 2026 in Review

Millennium Management increased its Structure Therapeutics (GPCR) stake by 11% in Q1 2026, buying an estimated $1.12M and bringing the position to 168,931 shares worth $8.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Millennium Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $44.7M in Q2 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Millennium Management held 168,931 shares of Structure Therapeutics worth $8.14M as of Q1 2026.
Millennium Management bought 16,371 Structure Therapeutics shares in Q1 2026, an estimated $1.12M.
Structure Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2379 holding.
Millennium Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
Millennium Management's Structure Therapeutics position peaked at $44.7M in Q2 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.